Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2008

01.01.2008 | Original Paper

Retrospective quantification of background incidence and stage distribution of breast cancer for the mammography screening pilot project in Wiesbaden, Germany

verfasst von: Gisela Schott, Margrit Reichel, Hans Junkermann, Nikolaus Becker

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Several parameters for quality assurance of mammography screening require background incidence rates, i.e. the breast cancer incidence in the absence of screening. For new programmes, incidence rates for the years prior to the programme are usually taken as a substitute with the appropriate source being cancer registries. In Germany, the feasibility of quality-assured screening was examined in three pilot projects over the years 2001–2005, so that background incidence was needed for quality assurance. Since countrywide cancer registration was not yet well established and especially in the pilot area of Wiesbaden an active cancer registry did not exist, other ways to obtain accurate rates were needed. Thus, in this pilot a manual data collection of breast cancer cases from diagnosing pathologic institutes was conducted to quantify local breast cancer incidence and compare it with available regional registry data from a distant part of the country. Results showed large similarities of rates for the mid of the 1990s, but a stronger increase of incidence for the subsequent years specifically in the pilot area. This increase was likely related to particular efforts in favour of opportunistic screening in that area. They led to increased detection of small cancers, but were too unsystematic to initiate decline of advanced breast cancers on the population level. In view of getting appropriate figures for background incidence these results indicate that emphasis should be put on using rates which are less affected by opportunistic screening rather than obtaining geographically proximate data. We propose to use the 50–69 years incidence rate of breast cancer for the years 1996–2000 in the Saarland cancer registry as background incidence rate which is almost identical to the Wiesbaden data for 1996 and 1997 but increased less strongly during 1998–2000. This incidence rate is 2.5 per 1,000, while that found in the Wiesbaden area was 2.7 per 1,000.
Literatur
Zurück zum Zitat Day NE, Williams DRR, Khaw KT (1989) Breast cancer screening programmes: the development of a monitoring and evaluation system. Int J Cancer 59:954–958 Day NE, Williams DRR, Khaw KT (1989) Breast cancer screening programmes: the development of a monitoring and evaluation system. Int J Cancer 59:954–958
Zurück zum Zitat Frischbier HJ, Hoeffken W, Robra BP (1994) Mammography in early detection of cancer (in German). Enke, Stuttgart Frischbier HJ, Hoeffken W, Robra BP (1994) Mammography in early detection of cancer (in German). Enke, Stuttgart
Zurück zum Zitat Giersiepen K, Haartje U, Hentschel S, Katalinic A, Kieschke J (2004) Stage distribution in the target population of mammography screening (in German). Deutsches Ärzteblatt A 101(30):2117–2122 Giersiepen K, Haartje U, Hentschel S, Katalinic A, Kieschke J (2004) Stage distribution in the target population of mammography screening (in German). Deutsches Ärzteblatt A 101(30):2117–2122
Zurück zum Zitat Junkermann H, Becker N, Peitgen H-O (2001) German pilot projects of mammography screening (in German). Der Radiologe 41:328–336PubMedCrossRef Junkermann H, Becker N, Peitgen H-O (2001) German pilot projects of mammography screening (in German). Der Radiologe 41:328–336PubMedCrossRef
Zurück zum Zitat Katalinic (2004) Population-based cancer registration in Germany. Essentials and perspectives (in German) Bundesgesundheitsblatt 47:422–428CrossRef Katalinic (2004) Population-based cancer registration in Germany. Essentials and perspectives (in German) Bundesgesundheitsblatt 47:422–428CrossRef
Zurück zum Zitat Köhler A, Gibis B, Mühlich A (2003) Mammographie-Screening. Flächendeckendes Angebot bereits im Jahr 2005. Dtsch Ärztebl A 100:1240–1243 (Heft 19) Köhler A, Gibis B, Mühlich A (2003) Mammographie-Screening. Flächendeckendes Angebot bereits im Jahr 2005. Dtsch Ärztebl A 100:1240–1243 (Heft 19)
Zurück zum Zitat Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol VIII. IARC Scientific Publications No. 155. International Agency for Research on Cancer, Lyon Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol VIII. IARC Scientific Publications No. 155. International Agency for Research on Cancer, Lyon
Zurück zum Zitat Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L, Puthaar E (eds) (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L, Puthaar E (eds) (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
Zurück zum Zitat Rittgen W, Becker N (2000) SMR-analysis of historical follow-up studies with missing death certificates. Biometrics 56:1164–1169PubMedCrossRef Rittgen W, Becker N (2000) SMR-analysis of historical follow-up studies with missing death certificates. Biometrics 56:1164–1169PubMedCrossRef
Metadaten
Titel
Retrospective quantification of background incidence and stage distribution of breast cancer for the mammography screening pilot project in Wiesbaden, Germany
verfasst von
Gisela Schott
Margrit Reichel
Hans Junkermann
Nikolaus Becker
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0239-4

Weitere Artikel der Ausgabe 1/2008

Journal of Cancer Research and Clinical Oncology 1/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.